Browsing by Subject "chronic myeloid-leukemia"
Now showing items 1-3 of 3
-
Clinical cardiac safety profile of nilotinib
(Ferrata Storti Foundation (Haematologica), 2012-01-22)Background Nilotinib is a second-generation tyrosine kinase inhibitor with significant efficacy as first-or second-line treatment in patients with chronic myeloid leukemia. Despite preclinical evidence indicating a risk ... -
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase cml patients treated with imatinib mesylate
(American Society of Hematology, 2004-01-15)We followed 141 patients treated with imatinib mesylate (>300 mg) for chronic-phase chronic myelogenous leukemia (CML) following failure of treatment with interferon. During 12 months from the start of imatinib mesylate ... -
The impact of clonal evolution on response to imatinib mesylate (sti571) in accelerated phase cml
(American Society of Hematology, 2002-05-13)